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OBJECTIVES Whether beta-blockers reduce atrial arrhythmias and, when added to an angiotensin-
converting enzyme (ACE) inhibitor, ventricular arrhythmia is unknown.
BACKGROUND Ventricular and atrial arrhythmias are common after acute myocardial infarction (AMI) and
are associated with a poor prognosis. Angiotensin-converting enzyme inhibitors reduce the
incidence of both types of arrhythmia.
METHODS The antiarrhythmic effect of carvedilol was examined in a placebo-controlled multicenter trial,
the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRI-
CORN) study, which enrolled 1,959 patients with reduced left ventricular systolic function
after AMI, 98% of whom were treated with an ACE inhibitor.
RESULTS The incidence of atrial fibrillation/flutter was 53 to 984 (5.4%) in the placebo group and 22
to 975 (2.3%) in the carvedilol group, giving a carvedilol/placebo hazard ratio (HR) of 0.41
(95% confidence interval [CI] 0.25 to 0.68; p  0.0003). The corresponding rates of
ventricular tachycardia/flutter/fibrillation were 38 to 984 (3.9%) and 9 to 975 (0.9%) (HR
0.24, 95% CI 0.11 to 0.49; p  0.0001).
CONCLUSIONS Carvedilol has a powerful antiarrhythmic effect after AMI, even in patients already treated
with an ACE inhibitor. Carvedilol suppresses atrial as well as ventricular arrhythmias in these
patients. (J Am Coll Cardiol 2005;45:525–30) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.09.076Cardiology Foundation
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Aardiac arrhythmias are common early after myocardial infarc-
ion (MI) and portend a poor prognosis (1–4). Elevated
ympathetic nervous system activity is one contributory mech-
nism and, by counteracting this, beta-adrenoceptor antago-
ists may reduce cardiac electrical instability (5–8). Most
See page 531
ttention has been paid to ventricular arrhythmias, and these
ere the focus of previous studies of the antiarrhythmic action
f beta-blockers after MI (9–13). It is also recognized, how-
ver, that atrial fibrillation (AF) results in a worse outcome
fter MI, although no placebo-controlled trial has examined
hether beta-blockers reduce the risk of atrial arrhythmias in
his setting (2,4,14–17).
More recently, angiotensin-converting enzyme (ACE)
nhibitors have been shown to reduce both ventricular and
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Manuscript received June 2, 2003; revised manuscript received August 26, 2004,
ccepted September 2, 2004.trial arrhythmias in higher risk post-MI patients (18–21).
t is not known whether beta-blockers, added to ACE
nhibitor treatment, will further reduce arrhythmias in these
atients.
The Carvedilol Post-Infarct Survival Control in Left Ven-
ricular Dysfunction (CAPRICORN) study was a multina-
ional prospective, randomized, event-driven, mortality/
orbidity trial carried out in patients with recent acute MI and
eft ventricular systolic dysfunction (22,23). All patients were
xpected to be treated with an ACE inhibitor (and 98% were).
atients were blindly allocated to placebo or carvedilol. This
nalysis describes the effect of carvedilol on the risk of atrial and
entricular arrhythmias.
ETHODS
he CAPRICORN trial. The design and primary results
f the CAPRICORN trial have been described in detail
lsewhere (22,23). Briefly, 984 patients were allocated to
lacebo and 975 were allocated to carvedilol between 3 to 21
ays post-MI (mean 10 days) and followed for an average of
.3 years. All prespecified end points (death and certain
ypes of cardiovascular hospitalization) were adjudicated by
blinded end point committee.
rrhythmia analysis. Cardiac arrhythmias were not a pre-pecified end point in the CAPRICORN trial. This analysis
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Antiarrhythmic Effect of Carvedilol February 15, 2005:525–30as, therefore, a post-hoc, though blinded, one. One end
oint committee member (J.M.) reviewed all adverse and
erious adverse event reports (AEs and SAEs) without
nowing treatment allocation. All events thought to be
elated to an arrhythmia were assigned to one of the
ollowing categories, which were decided upon before the
nalysis was undertaken:
trial arrhythmias: 1) any report of supraventricular ectopic
beats, atrial tachycardia, atrial flutter, AF, or any other
“supraventricular tachycardia,” excluding sinus tachycar-
dia; 2) AF/atrial flutter only.
entricular arrhythmias: 1) any report of ventricular ectopic
beats, ventricular tachycardia, ventricular fibrillation, or
ventricular flutter; 2) “malignant” ventricular arrhyth-
mias only (i.e., ventricular tachycardia, ventricular fibril-
lation, and ventricular flutter).
rrhythmias were identified and characterized according to
he AE narrative, and electrocardiogram confirmation was
ot available.
rior arrhythmias. Information on prior arrhythmias was
ollected in two ways. Investigators were asked to complete a
medical history” form at the screening visit. This form sought
nformation on prior or ongoing problems. Investigators were
lso asked to complete a “signs and symptoms” baseline visit
orm at the time of randomization, designed to identify any
hanges in the patients’ clinical condition from screening. The
aseline visit usually occurred on the same date as screening,
ut could take place later. Because 5% of patients have a
revious or ongoing atrial arrhythmia recorded at their screen-
ng visit, two sets of analyses were performed. The main
nalysis used all randomized patients. A separate analysis was
arried out in the subset of patients without a history of atrial
rrhythmias. A similar secondary analysis was performed for
atients with prior or recent ventricular arrhythmias.
ombined outcomes. To take account of the issue of
competing risks,” in relation to the different survival rates
n the two treatment groups (whereby deceased patients
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
AE  adverse event
AF  atrial fibrillation
CAPRICORN  Carvedilol Post-Infarct Survival
Control in Left Ventricular
Dysfunction trial
CI  confidence interval
DIAMOND-MI  Danish Investigations of Arrhythmia
and Mortality on Dofetilide-
Myocardial Infarction study
HR  hazard ratio
MI  myocardial infarction
SAE  serious adverse event
TRACE  Trandolapril Cardiac Evaluation
studyannot be at risk of an arrhythmia), we also examined a Mumber of combined outcomes, taking account of death or
n arrhythmia.
tatistical analysis. All analyses were carried out on an
ntention-to-treat basis. All outcomes were analyzed using a
ime-to-first-event approach. The statistical significance of
reatment comparisons was based on the log-rank test. Hazard
atios (HR) and 95% confidence intervals (CIs) were derived
rom the fitting of Cox proportional hazards regression models
ith treatment assignment as the only factor. Cumulative
ncidence curves, which adjust for competing risks for censor-
ng due to all-cause mortality, were used to show the accrual of
vents with time in the two treatment groups (24).
The distribution of age at baseline is presented as mean
nd the range and categorical baseline characteristics are
hown as percentages.
ESULTS
he baseline characteristics of the patients randomized in
APRICORN are shown in Table 1. A total of 9% of
atients (89 placebo group, 81 carvedilol group) were
ecorded as having a prior or ongoing history of AF/atrial
utter, and 1.1% were identified as having had ventricular
achycardia (2 placebo group, 0 carvedilol group) or fibril-
ation (14 placebo group, 6 carvedilol group).
A total of 96 patients (5%) were treated with an antiar-
hythmic drug at the time of randomization, and, in 95 of
hese 96, the treatment used was amiodarone (59 placebo
roup, 36 carvedilol group).
able 1. Baseline Characteristics of Patients
Placebo
(n  984)
Carvedilol
(n  975)
ean (range) age (yrs) 63 (25–90) 63 (29–88)
ales (%) 74 73
ast medical history (%)*
MI 29 31
Angina 54 57
Hypertension 52 55
Diabetes mellitus 23 21
Coronary revascularization 11 12
Atrial fibrillation/flutter 9 8
Ventricular fibrillation 1.4 0.6
ite of AMI (%)
Anterior 54 59
Inferior 21 21
Other 25 20
reatment for index AMI (%)
Thrombolysis/primary PCI 47 45
Intravenous diuretic 33 35
edication at randomization (%)
Amiodarone 6 4
Other antiarrhythmic drug 1 0
ACE inhibitor 97 98
Aspirin 86 86
Warfarin 5 5
Past or ongoing.
ACE  angiotensin-converting enzyme; AMI  acute myocardial infarction;
I  myocardial infarction; PCI  percutaneous coronary intervention.
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February 15, 2005:525–30 Antiarrhythmic Effect of Carvedilolupraventricular arrhythmias. ANY SUPRAVENTRICULAR
RRHYTHMIA. Among carvedilol-treated patients, 26 of
75 (2.7%) had a report of a supraventricular arrhythmia
ompared with 54 of 984 (5.5%) of placebo-treated patients,
epresenting a carvedilol/placebo HR of 0.48 (95% CI 0.30
o 0.76; log-rank p 0.0015). After excluding patients with
history of AF/atrial flutter, 19 of 894 (2.1%) of carvedilol-
reated patients and 32 of 895 (3.6%) of placebo-treated
atients had a report of a supraventricular arrhythmia after
andomization: HR 0.59 (95% CI 0.33 to 1.03; p  0.062).
F/ATRIAL FLUTTER. The comparable rates of AF/atrial
utter in the carvedilol and placebo groups were 22 of 975
2.3%) and 53 of 984 (5.4%), respectively, representing an
R of 0.41 (95% CI 0.25 to 0.68; p  0.0003) (Fig. 1).
fter excluding patients with a history of AF/atrial flutter,
6 of 894 (1.8%) carvedilol-treated patients and 31 of 895
3.5%) placebo patients had a report of AF/atrial flutter after
andomization: HR 0.51 (95% CI 0.28 to 0.93; p  0.025).
entricular arrhythmias. ANY VENTRICULAR ARRHYTHMIA.
mong carvedilol-treated patients, 26 of 975 (2.7%) had a
eport of a ventricular arrhythmia compared with 69 of 984
7.0%) placebo-treated patients, representing an HR of 0.37
95% CI 0.24 to 0.58; p 0.0001) (Fig. 2). Among carvedilol-
reated patients, there were 4 episodes of ventricular fibrilla-
ion/flutter, 6 of ventricular tachycardia, and 19 of other
entricular arrhythmias (premature beats, couplets, and so on).
n the placebo group, these numbers were 17, 27, and 38,
espectively.
After excluding patients with a history of ventricular
brillation/tachycardia, 25 of 969 (2.6%) carvedilol-treated
atients and 66 of 968 (6.8%) placebo-treated patients had
report of a ventricular arrhythmia after randomization:
R 0.37 (95% CI 0.23 to 0.59; p  0.0001).
MALIGNANT” VENTRICULAR ARRHYTHMIAS. The compa-
able rates of ventricular tachycardia, ventricular fibrillation,
r ventricular flutter were 9 of 975 (0.9%) in the carvedilol
roup and 38 of 984 (3.9%) in the placebo group, repre-
enting an HR of 0.24 (95% CI 0.11 to 0.49; p  0.0001).
ombined outcomes. Table 2 shows the combined out-
omes of death or an arrhythmia. Carvedilol reduced the
isk of all combined outcomes analyzed, including the
utcome of death or any reported arrhythmia.r
igure 1. Survival free of atrial fibrillation or atrial flutter. Dotted line 
lacebo; solid line  carvedilol.rrhythmias and sudden death. Table 3 shows the rela-
ionship between arrhythmias and death from any cause and
hose adjudicated as sudden. Patients who experienced an
rrhythmia were more likely to die and to have their mode
f death classified as “sudden.” There was a nonsignificant
rend for fewer sudden deaths in the carvedilol group,
specially in patients with an arrhythmia.
ISCUSSION
n this retrospective, but blinded, analysis of the CAPRI-
ORN trial, carvedilol was shown to have a striking effect,
ot only on the incidence of ventricular arrhythmias but also
n the risk of atrial arrhythmias.
The occurrence of AF after MI is associated with a worse
linical outcome, including a higher mortality (2–4,14–17).
his is the case generally and also in patients with significant
eft ventricular systolic dysfunction after infarction. For exam-
le, the Trandolapril Cardiac Evaluation (TRACE) investiga-
ors found that AF was an independent predictor of both a
igher in-hospital and long-term mortality (4). In the
RACE study, the risk of developing AF, over a mean
ollow-up of 2.2 years, was reduced in the ACE inhibitor
roup (n  22, 2.8%) compared with the placebo group (n 
2, 5.3%) (21).
Whether beta-blockers reduce the risk of atrial arrhythmias
fter MI has not been tested in a double-blind prospective,
andomized, placebo-controlled trial, particularly in patients
lready treated with an ACE inhibitor. This analysis of the
APRICORN trial suggests that carvedilol markedly sup-
resses atrial arrhythmias in these patients. It is of interest to
ompare these findings with the recent Danish Investigations
f Arrhythmia and Mortality on Dofetilide-Myocardial Infarc-
ion (DIAMOND-MI) study, which examined the effect of a
ew class III antiarrhythmic agent in similar patients with
hose enrolled in the TRACE and CAPRICORN trials (25).
n the DIAMOND-MI study 58% of patients were treated
ith an ACE inhibitor and 36% with a beta-blocker at the
ime of randomization (25). The risk of developing AF or atrial
utter, over a mean follow-up of 1.25 years, in patients in sinus
igure 2. Survival free of any ventricular arrhythmia. Dotted line 
lacebo; solid line  carvedilol.hythm at baseline was 14 of 705 (2.0%) in the placebo group
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Antiarrhythmic Effect of Carvedilol February 15, 2005:525–30nd 5 of 690 (0.7%) in the dofetilide group (approximately 65%
isk reduction, p  0.09) (25).
The effect of beta-blockers on ventricular arrhythmias in the
ost-MI setting is more clearly established. Both substudies of
he large beta-blocker secondary prevention trials and indepen-
ent studies showed significant reductions in all grades of
entricular arrhythmias with propranolol, timolol, and meto-
rolol (9–13,26–29). None of these studies, however, focused
n patients with substantial left ventricular systolic dysfunction;
ndeed, it seems that high-risk patients were excluded from
hese studies (22,23). Furthermore, these studies were con-
ucted before the benefits of ACE inhibitors, one of which is
o reduce ventricular arrhythmias, had been established
19,30,31). We were able to confirm that carvedilol reduced
entricular arrhythmias, even in high-risk patients treated with
n ACE inhibitor. Indeed, the magnitude of this effect, be it on
ll ventricular arrhythmias or just “malignant” arrhythmias, was
triking; the latter were reduced by 70%. Whether the size of
his effect reflects just the beta-blocking action of carvedilol or
n additional antiarrhythmic action of the molecule (for exam-
le, carvedilol has been shown, in vitro, to block HERG
otassium channels) cannot be determined from the current
tudy (32,33).
able 3. Arrhythmia and Mode of Death
Placebo
(No Arrhythmia
n  867,
Arrhythmia,
n  117)
Carvedilol
(No Arrhythmia,
n  924,
Arrhythmia,
n  51)
eath from any cause*
No arrhythmia 116 (13.4%) 103 (11.1%)
Arrhythmia 35 (29.9%) 13 (25.5%)
udden death†
No arrhythmia (n  924) 53 (6.1%) 46 (5.0%)
Arrhythmia (n  51) 16 (13.7%) 5 (9.8%)
14 subjects in the placebo group died within 2 days of the arrhythmia report
ompared with 1 in the carvedilol group; †8 subjects in the placebo group experienced
able 2. Combined Outcomes of Death or Arrhythmia
Outcome
eath or SV arrhythmia
eath or SV arrhythmia (excluding patients with a history of AF/AFL)
eath or AF/AFL
eath or AF/AFL (excluding patients with a history of AF/AFL)
eath or any ventricular arrhythmia
eath or any ventricular arrhythmia (excluding patients with a history
of VT/VF)
eath or a malignant ventricular arrhythmia
eath or any arrhythmia
F/AFL  atrial fibrillation/atrial flutter; CI  confidence interval; SV  supravenudden death within 2 days of the arrhythmia report compared with 0 in the carvedilol
roup.That the substantial reduction in “malignant” ventricular
rrhythmias did not translate into a clearly significant reduction
n sudden death (placebo 69 of 984 [7%], carvedilol 51 of 975
5%]; p 0.098), as reported in the main CAPRICORN trial
esults paper (23), might, at first sight, seem surprising.
owever, with only 120 sudden deaths in total, we had low
tatistical power to detect such a treatment effect. Furthermore,
ny such treatment effect might have been diluted by nonar-
hythmic causes of sudden death such as bradycardia/asystole,
ulmonary embolism, reinfarction leading to catastrophic
ump failure, stroke, and other noncoronary vascular events
e.g., aortic aneurysm rupture) the risk of which may not be
educed by beta-blockade (34). The use of amiodarone in a
mall proportion of patients might have similarly reduced our
bility to show a difference between carvedilol and placebo.
urthermore, further analysis of mode of death in those
xperiencing an arrhythmia showed a strong trend to fewer
udden deaths in the carvedilol group.
The present analysis has a number of limitations. First, it
as not prespecified. Second, it is based on an examination of
Es and SAEs without electrocardiographic validation of
rrhythmias. Spontaneous AE and SAE reporting might be
xpected to underestimate the true incidence of arrhythmias.
omparison with other recent studies (e.g., the TRACE and
IAMOND studies), however, suggests that this is not the
ase for supraventricular arrhythmias (i.e., our rates of arrhyth-
ias were similar to the rates reported in those other trials).
e also believe that under- or overreporting of clinically
mportant ventricular arrhythmias is unlikely. The recent
plerenone Post-Acute Myocardial Infarction Heart Failure
fficacy Survival Study (EPHESUS) is useful for comparison.
ver an average follow-up of 1.33 years, 54 of 3,313 (1.6%) of
lacebo-treated patients (75% of whom were treated with a
eta-blocker) were hospitalized for a ventricular arrhythmia. In
he carvedilol group in the CAPRICORN trial, 9 of 975
0.9%) of patients experienced a “malignant” ventricular ar-
hythmia over 1.3 years compared with 38 of 984 (3.9%) in the
lacebo group.
Subjects With Event
Carvedilol (n  975)/
Placebo (n  984)
Carvedilol/Placebo
Hazard Ratio
(95% CI)
Log-Rank
p Value
133/187 0.70 (0.56, 0.88) 0.0016
112/152 0.72 (0.57, 0.92) 0.0090
129/186 0.68 (0.55, 0.85) 0.0008
109/151 0.71 (0.55, 0.91) 0.0057
138/201 0.67 (0.54, 0.84) 0.0003
137/197 0.68 (0.54, 0.84) 0.0004
123/173 0.70 (0.56, 0.89) 0.0028
154/233 0.64 (0.52, 0.79) 0.0001
r; VT/VF  ventricular tachycardia/ventricular fibrillation.triculaHowever, spontaneous reporting might exaggerate the
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February 15, 2005:525–30 Antiarrhythmic Effect of Carvedilolpparent antiarrhythmic effect of carvedilol because this
rug is likely to reduce awareness of an arrhythmia.
What are the clinical implications of these findings? We
elieve that they reinforce the value of beta-blockers as essen-
ial treatment in patients with acute infarction (35). Though
ther treatments (i.e., an implantable cardioverter defibrillator
36] and eplerenone [37]) reduce the risk of sudden death (and
eath from any cause) in patients already taking a beta-blocker,
arvedilol also reduces the risk of reinfarction (as do other
eta-blockers) and of atrial arrhythmias.
In summary, in this nonprespecified analysis, carvedilol
ppeared to reduce the incidence of investigator-reported (but
onadjudicated) atrial and ventricular arrhythmias in patients
ith acute MI and associated impairment of left ventricular
ystolic dysfunction. This antiarrhythmic effect is additional to
hat known to be exerted by ACE inhibitors in these patients.
.
eprint requests and correspondence: Prof. John J. V. McMur-
ay, Department of Cardiology, Western Infirmary, Glasgow,
11 6NT, United Kingdom. E-mail: j.mcmurray@bio.gla.ac.uk.
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